A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients

Inclusion Criteria: \- Previously enrolled in the MIV-711-201 study including completion of Visit 8 either by * Receiving MIV-711 200 mg and had non-significant clinical worsening on the primary endpoint as defined by a Numeric Rating Scale (NRS) increase of ≤2 OR by * Receiving placebo and had a clinically significant worsening on the primary endpoint as defined by a NRS increase of ≥2 Exclusion Criteria: * The presence of any inflammatory arthritis * Any generalized pain condition that may interfere with the evaluation of the target knee pain (e.g., fibromyalgia) as judged by the investigator. * Any clinically severe or significant uncontrolled concurrent illness, which, in the opinion of the Investigator, would impair ability to give informed consent or take part in or complete this clinical study. * Known or suspected intolerance or hypersensitivity to the investigational product, closely related compounds, or any of the stated ingredients.